SAN DIEGO -- The investigational monoclonal antibody marstacimab reduced the rate of treated bleeds in patients with hemophilia A or B without inhibitors to factor VIII or factor IX, the phase III ...
Oct. 14, 2024 – The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year. Hemophilia is a ...
Interv Cardiol. 2009;1(1):51-62. Table 2 provides a listing of some of the bleeding definitions used in PCI clinical trials and registries. This table illustrates the wide spectrum of bleeding ...
Once-weekly prophylaxis with efanesoctocog alfa (Altuviiio) led to high sustained factor VIII activity and was effective in preventing bleeding among children with severe hemophilia A, the phase III ...
The 30-day mortality rate after emergent abdominal surgery is twice as high for patients on dialysis who experience major bleeding. Patients on dialysis experience high rates of bleeding requiring ...
Cumulative safety data from three trials testing the reversible direct factor XIa inhibitor asundexian in patients at risk for stroke or recurrent cardiovascular events suggest a better bleeding ...
Please provide your email address to receive an email when new articles are posted on . Rivaroxaban was linked to higher rates of major bleeding compared with low-dose aspirin. Apixaban and dabigatran ...
WASHINGTON, DC—In the DanGer Shock trial of Impella CP (Abiomed) in patients with STEMI complicated by cardiogenic shock (STEMI-CS), bleeding occurs not just in the cath lab but also while on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback